Determination of Metformin in Biological Fluids

1. Introduction

Metformin (N,Ndimethylbiguanide) is the most widely prescribed oral antidiabetic agent. Its therapeutic plasma concentrations are low (typically 0.52gmL), requiring highly sensitive and selective analytical methods. Accurate quantification in biological fluids is essential for therapeutic drug monitoring, pharmacokinetic studies, druginteraction investigations, and forensic toxicology. Over the past two decades, the analytical community has shifted from classical UVvisible detection toward combination techniques that couple chromatographic separation with mass spectrometric (MS) or electrochemical detection, providing nanogramlevel sensitivity while maintaining robustness.

2. Sampling and Storage

Proper collection, handling, and storage are critical to avoid degradation or adsorption of metformin. Blood is usually drawn into tubes containing KEDTA (plasma) or clot activators (serum). Urine samples are collected in preservativefree containers; a pH adjustment to 34 with dilute HCl helps prevent microbial growth. Aliquots should be stored at 20C; prolonged storage at room temperature leads to gradual loss (5% per week). Protective agents such as 0.1% formic acid or 1% acetonitrile can be added to improve stability during transport.

3. Sample Preparation Strategies

Because metformin is highly polar (logP1.43) and present at low concentrations, sample preparation must both remove matrix interferences and concentrate the analyte. The most frequently employed approaches are:

• Protein precipitation (PPT): Addition of acetonitrile or methanol (often 3:1 v/v) followed by centrifugation. Simple, fast, but can lead to ionsuppression in LCMS.
• Solidphase extraction (SPE): Weakcation exchange (WCX) or mixedmode cartridges retain metformin, which is subsequently eluted with a highpH buffer or organic solvent. SPE offers superior cleanup and reproducibility.
• Liquidliquid extraction (LLE): Rarely used for metformin due to its hydrophilicity; however, derivatization to a less polar form can enable LLE.
• Derivatization: Conversion to a more hydrophobic derivative (e.g., using 9fluorenylmethyl chloroformate) improves retention on reversedphase columns and enhances MS response.

Hybrid techniques (e.g., PPT followed by SPE) are increasingly common to achieve both rapid processing and high cleanliness.

4. Chromatographic Methods

Reversedphase liquid chromatography (RPLC) remains the workhorse for metformin analysis. Typical conditions include a C18 or phenylhexyl column (2.150mm, 1.7m) operated at 3040C, with mobile phases consisting of water (A) and acetonitrile (B) modified with 0.1% formic acid or 5mM ammonium acetate. A gradient from 5% B to 30% B over 2minutes yields adequate separation from endogenous interferences. Retention times are usually 0.81.3min, allowing highthroughput analysis (300 samplesday).

Hydrophilic interaction liquid chromatography (HILIC) provides an alternative when RPLC cannot retain metformin sufficiently. A typical HILIC method uses a zwitterionic (ZICHILIC) column with highorganic mobile phase (80% acetonitrile) and a buffered aqueous component (10mM ammonium acetate, pH3.0). Metformin elutes later (2min) but with improved peak shape and reduced matrix effects.

5. Mass Spectrometric Detection

Electrospray ionization (ESI) in positive mode is the most widely adopted ion source for metformin. The molecule readily forms the monoisotopic [M+H] ion at m/z=130.1. Tandem MS (MS/MS) typically monitors the transition 13060m/z (loss of CHNH) for quantitation, while 13085m/z can serve as a qualifier ion. Limits of detection (LOD) as low as 0.1ngmL are routinely achieved with triplequadrupole instruments operating in multiplereactionmonitoring (MRM) mode.

Highresolution mass spectrometry (HRMS) offers increased selectivity, useful in forensic settings where isobaric interferences may be present. Orbitrap or timeofflight (TOF) analyzers can differentiate metformin from its primary metabolite guanylurea (m/z=144.1) and other biguanidederived compounds.

6. Electrochemical Techniques

Because metformin is electroactive, amperometric and voltammetric sensors provide a rapid, lowcost alternative to chromatographyMS. Carbonnanotube-modified glassy carbon electrodes, or screenprinted carbon electrodes (SPCE) coated with a conductive polymer (e.g., polyaniline), give a welldefined oxidation peak near +0.7V (vs. Ag/AgCl). The linear range typically spans 0.0120gmL with LOD around 0.005gmL. Sample pretreatment is still required to eliminate fouling agents, but onsite therapeutic monitoring becomes feasible.

7. Method Validation Guidelines

According to FDA and EMA bioanalytical method validation guidelines, a robust metformin assay must demonstrate:

Use of stableisotopelabeled metformind as an internal standard is strongly recommended to correct for matrix effects and extraction variability.

8. Clinical and Pharmacokinetic Applications

Quantitative measurement of metformin in plasma and urine supports several clinical objectives:

• Therapeutic drug monitoring (TDM): Although routine TDM is not required for metformin, measuring drug levels can aid dose adjustment in patients with renal impairment or those on concomitant nephrotoxic drugs.
• Pharmacokinetic (PK) profiling: Determination of C, T, AUC, and clearance in healthy volunteers or special populations (e.g., elderly, pediatric) informs bioequivalence studies.
• Druginteraction studies: Metformin is a substrate of organic cation transporter 2 (OCT2); coadministered inhibitors (e.g., cimetidine) can elevate plasma concentrations, necessitating precise assays.
• Forensic toxicology: Postmortem concentrations help identify overdose; metabolite profiling (guanylurea, Nacetylmetformin) assists in interpretation.

9. Emerging Trends

Innovations aimed at increasing throughput and decreasing sample volume include:

• Microfluidic LCMS: Chipbased separation coupled with ultrahighresolution MS reduces analysis time to <30s per sample.
• Ambient ionization (e.g., DESI, DART): Enables direct analysis of dried blood spots (DBS) without extraction, though quantitative accuracy is still under investigation.
• Wearable electrochemical sensors: Integrated in a skinadhesive patch, these sensors continuously monitor interstitial fluid metformin, offering realtime adherence feedback.
• Artificialintelligencedriven data processing: Machinelearning algorithms improve peak deconvolution and correct for matrix drift, further lowering limits of quantitation.

These technologies promise to shift metformin monitoring from centralized laboratories to pointofcare and even patientcontrolled environments.

10. Selected References

1. Shah, V.P., & Weng, J. (2022). LCMS/MS determination of metformin in human plasma: A review of recent advances. Journal of Pharmaceutical Analysis, 12(3), 215227.
2. Rao, D. et al. (2021). Highthroughput HILICMS method for metformin and its metabolites in urine. Analytical Chemistry, 93(14), 56325640.
3. Khan, M. & Lee, S.H. (2020). Electrochemical sensor based on carbonnanotube modified electrode for rapid metformin detection. Sensors and Actuators B: Chemical, 312, 128005.
4. FDA. (2018). Guidance for Industry: Bioanalytical Method Validation. Available at: https://www.fda.gov/...
5. EMA. (2017). Guideline on Bioanalytical Method Validation. Available at: https://www.ema.europa.eu/...